ID   MB49luc
AC   CVCL_E8D4
SY   MB49-luciferase; MB49 LucSH+
RX   PubMed=26921031;
WW   Provider; NCI TTC; TAB-4085/E-237-2018-0; https://techtransfer.cancer.gov/available-technologies?abstract=TAB-4085
CC   Characteristics: Transfected with a pSELECT-zeo-LucSh which contains a synthetic CpG-free firefly Luc-Zeocin fusion protein (PubMed=26921031).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
CC   Transformant: ChEBI; CHEBI_254496; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
CC   Breed/subspecies: C57BL/ICRF-a(t).
DI   NCIt; C25823; Mouse bladder transitional cell carcinoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_7076 ! MB49
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=26921031; DOI=10.1158/2326-6066.CIR-15-0176; PMCID=PMC4881865;
RA   Vandeveer A.J., Fallon J.K., Tighe R.V., Sabzevari H., Schlom J.,
RA   Greiner J.W.;
RT   "Systemic immunotherapy of non-muscle invasive mouse bladder cancer
RT   with avelumab, an anti-PD-L1 immune checkpoint inhibitor.";
RL   Cancer Immunol. Res. 4:452-462(2016).
//